medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 2

<< Back Next >>

Ann Hepatol 2012; 11 (2)

The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study

García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, Villarreal-Pérez JZ, Maldonado-Garza HJ

Language: English
References: 41
Page: 240-248
PDF size: 159.24 Kb.


ABSTRACT

Aims. To define the prevalence and clinical characteristics of glucose metabolism disorders (GMD) in patients with compensated liver cirrhosis (LC). Material and methods. Fasting plasma glucose (FPG) levels were measured to 130 patients with clinically stable LC. Oral glucose tolerance tests (OGTT) and fasting plasma insulin determinations were performed to patients with normal FPG. Insulin resistance (IR) was calculated with HOMA2-IR index. GMD were classified according to FPG and OGTT tests results and to the chronologic relation between diagnosis of diabetes mellitus (DM) and LC as follows: type-2 DM (T2DM), hepatogenous diabetes (HD) and impaired glucose tolerance. Patients from all groups were compared. Results. The prevalence of GMD were as follows: T2DM in 25 patients (19.2%, 95% CI 12.5-25.9), HD in 28 (21.5%, 95% CI 14.5-28.5) and IGT in 36 (38.5%, 95% CI 30.1-46.7). The total of patients with GMD was 79.2% (95% CI 72.3-86.1). In 41% of cases GMD were subclinical and 48.7% of patients had IR. Patients with T2DM had a higher number of variables with significant differences compared with the other groups (more marked compared to the patients without GMD). The only differences between the patients with T2DM and HD were hypercreatininemia: 1.14 ± 0.53 vs. 0.84 ± 0.22 mg/dL (p = 0.005) and family history of DM: 8 (32%) vs. 2 (7%) (p = 0.02). Conclusion. Almost 80% of patients with compensated LC had GMD. Half of them were subclinical. The patients with T2DM had marked clinical differences compared to patients from the other groups, particularly renal impairment.


REFERENCES

  1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.

  2. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci 2010; 55: 560-78.

  3. Blendea MC, Thompson MJ, Malkani S. Diabetes and chronic liver disease: Etiology and pitfalls in monitoring. Clin Diabetes 2010; 28: 139-44.

  4. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: 526-31.

  5. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes: current views of an ancient problem. Ann Hepatol 2009: 8: 13-20.

  6. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

  7. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

  8. Del Vecchio-Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

  9. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.

  10. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, Afeltra A. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev 2006; 22: 274-83.

  11. Nielsen MF, Caumo A, Aagaard NK, Chandramouli V, Schumann WC, Landau BR, Schmitz O, et al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1135-43.

  12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2011; 34(Suppl. 1): S62-S69.

  13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.

  14. Cortez-Pinto H, Carneiro de Moura M, Paul Day C. Non-alcoholic steatohepatitis: From cell biology to clinical practice. J Hepatol 2006; 44: 197-208.

  15. Raddatz D, Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 2007; 45: 51-62.

  16. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

  17. Jáquez-Quintana JO, García-Compean, González-González JA, Villarreal-Pérez JZ, Lavalle-González FJ, Muñoz- Espinosa LE, López-Hernández PL, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.

  18. Nguyen DM, El-SeragHB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.

  19. Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo-Arvizu R, Kanter R, Rivera JA. Obesidad y adiposidad central en adultos mexicanos: resultados de la Encuesta Nacional de Salud y Nutrición 2006. Sal Pub Mex 2009; 51(Suppl. 4): S595-S603.

  20. Tellez FI, Sanchez F, Garcia M, Chavez Tapia N, Franco AM, Lopez G, Cerda E, et al. Prevalence of metabolic síndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-5.

  21. Macías-Rodríguez RU, Torre A. Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview. Rev Invest Clin 2009; 61: 4771-5.

  22. Romero-Gomez M, Viloria MM, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Copras R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636.

  23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.

  24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

  25. Patrick S, Kamath W, Ray Kim. The Model for End-Stage Liver Disease (MELD). Hepatology 2007; 45: 797-805.

  26. Kobashi-Margáin RA, Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol 2010; 9: 282-8.

  27. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 21; 15: 280-8.

  28. Cortez-Pinto H, Carneiro de Moura M, Paul Day C. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38-46.

  29. Wree A, Kahraman A, Gerken G, Canbav A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 2011; 83: 124-33.

  30. Goral V, Atalay R, Kucukoren M. Insulin resistance in liver cirrhosis. Hepatogastroenterology 2010; 57: 309-15.

  31. Molitch ME, De Fronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. American Diabetes Association. Nephropathy in diabetes. Diab Care 2004; 27(Suppl.1): S79-S83.

  32. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-96.

  33. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, et al. Cardiovascular disease in cirrhosisa point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655-62.

  34. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-48.

  35. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diab Obes Metab 2006; 8: 264-80.

  36. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101.

  37. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-36.

  38. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-51.

  39. Tietge UJ, Böker KH, Manns MP, Bahr MJ l. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: 82-9.

  40. Sorrentino P, Tarantino G, Conca P, Perrella A, Perella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. Can J Gastroenterol 2004; 18: 381-6.

  41. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol 2007; 41: 403-11.




2020     |     www.medigraphic.com